What were the main drivers of Cardinal Health's revenue growth in Q2 FY2024?

Cardinal Health's revenue increased by 12% to $57.4 billion, primarily driven by growth in branded and specialty pharmaceutical sales from existing customers within its Pharmaceutical segment. The Medical segment also contributed with sales growth in at-Home Solutions and products and distribution, including higher Cardinal Health brand volumes and price increases to offset inflation.

How did the company's profitability improve in Q2 FY2024?

Profitability improved significantly, with GAAP operating earnings turning positive at $482 million compared to a loss of $119 million in the prior year. Non-GAAP operating earnings increased by 20% to $562 million, and non-GAAP diluted EPS rose by 38% to $1.82. These improvements were supported by increased profit in both the Pharmaceutical and Medical segments, despite excluding large items like goodwill impairment charges.

What is the strategic significance of the announced acquisition of Specialty Networks?

The acquisition of Specialty Networks for $1.2 billion is a key strategic move designed to expand Cardinal Health's offerings in critical therapeutic areas. It aims to enhance downstream provider-focused analytics capabilities and service offerings, while also accelerating upstream data and research opportunities with biopharma manufacturers.

How is the company managing its liquidity and capital deployment?

Cardinal Health maintains a strong liquidity position, with cash and equivalents at $4.6 billion as of December 31, 2023. Net cash provided by operating activities was $1.7 billion for the first six months of FY2024. The company is actively returning capital to shareholders through share repurchases ($750 million in the period) and dividends ($255 million paid). The company also has significant unused credit facilities and a $3.5 billion share repurchase authorization remaining.

CAH 10-Q Quarterly Report Q2 FY2024 — Revenue, Net Income, EPS

Summary

Cardinal Health Inc. (CAH) reported a strong second quarter for fiscal year 2024, with total revenue increasing by 12% year-over-year to $57.4 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical segment. The company also demonstrated significant improvements in profitability, with non-GAAP operating earnings up 20% and non-GAAP diluted EPS rising 38% year-over-year. This enhanced performance is attributed to stronger contributions from both the Pharmaceutical and Medical segments. Looking ahead, Cardinal Health announced a significant strategic move with the definitive agreement to acquire Specialty Networks for $1.2 billion in cash. This acquisition is expected to bolster the company's offerings in key therapeutic areas by enhancing analytics capabilities and accelerating data and research opportunities with biopharma manufacturers. The company also maintains a healthy liquidity position, with cash and equivalents increasing to $4.6 billion, supported by robust operating cash flow, and continues its capital return strategy through share repurchases and dividends.

Financial Highlights

49 data points

Beta

Revenue

$57.44B

0.0% Gross Margin

Net Income

$368.00M

0.0% Net Margin

EPS (Diluted)

$1.50

Total Assets

$46.57B

Cash & Equivalents

$4.60B

Free Cash Flow

$1.06B

Financial Statements

Beta

Revenue	$57.44B
Cost of Revenue	$55.59B
Gross Profit	$1.85B
SG&A Expenses	$1.27B
Operating Income	$505.00M
Interest Expense	$3.00M
Net Income	$368.00M
EPS (Basic)	$1.50
EPS (Diluted)	$1.50
Shares Outstanding (Basic)	245.00M
Shares Outstanding (Diluted)	246.00M

Key Highlights

1Revenue increased 12% to $57.4 billion for Q2 FY2024, driven by pharmaceutical sales growth.
2Non-GAAP operating earnings grew 20% to $562 million, and non-GAAP diluted EPS increased 38% to $1.82 year-over-year.
3Announced definitive agreement to acquire Specialty Networks for $1.2 billion to expand offerings in key therapeutic areas.
4Pharmaceutical segment profit increased 12%, benefiting from generics program performance and COVID-19 vaccine distribution.
5Medical segment profit saw a significant increase due to favorable comparisons to prior-year inflationary impacts and mitigation actions.
6Cash and equivalents increased to $4.6 billion at December 31, 2023.
7Completed $750 million in share repurchases and paid $255 million in dividends during the first six months of FY2024.

CARDINAL HEALTH INC Quarterly Report for Q2 Ended Dec 31, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions